Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 18/20 | 0.54 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.51 |
| ▸ | KIF11 | P52732 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20983702 | 0.86 | TRPV1 (0.60) | TRPV1SCN5ASCN9A | |
| SCHEMBL15624412 | 0.83 | TRPV1 (0.47) | TRPV1 | |
| SCHEMBL3138189 | 0.81 | CYP2A6 (0.56) | TRPV1SCN5ASCN9A | |
| SCHEMBL3702161 | 0.81 | TRPV1 (0.67) | TRPV1 | |
| SCHEMBL27637538 | 0.81 | TRPV1 (0.52) | TRPV1SCN5ASCN9A | |
| SCHEMBL30115268 | 0.81 | CYP2A6 (0.56) | TRPV1SCN5ASCN9A | |
| SCHEMBL4972991 | 0.81 | TRPV1 (0.52) | TRPV1 | |
| SCHEMBL6195448 | 0.81 | TRPV1 (0.56) | TRPV1 | |
| SCHEMBL9823570 | 0.79 | TRPV1 (0.50) | TRPV1 | |
| SCHEMBL19072734 | 0.78 | TRPV1 (0.52) | TRPV1SCN5ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319683-B2 | Azabenzimidazole compounds and pharmaceutical | NIPPON SHINYAKU CO., LTD. (JP) | 2025-06-03 | — | — | US | disclosed |
| US-20230002395-A1 | AZABENZIMIDAZOLE COMPOUND AND MEDICINE | NIPPON SHINYAKU CO., LTD. (JP) | 2023-01-05 | — | — | US | disclosed |
| US-20230000840-A1 | THERAPEUTIC AGENTS AND PROPHYLACTIC AGENTS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS AND XEROSTOMIA | NIPPON SHINYAKU CO., LTD. (JP) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002395-A1 | AZABENZIMIDAZOLE COMPOUND AND MEDICINE | PAM, CHRM3, AZI2 | TRPV1 30/4885SCN5A 1622/4885SCN9A 2513/4885 |
| US-20230000840-A1 | THERAPEUTIC AGENTS AND PROPHYLACTIC AGENTS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS AND XEROSTOMIA | ALPI, SI, AZI2 | TRPV1 624/4885SCN5A 1191/4885SCN9A 2291/4885 |
| US-12319683-B2 | Azabenzimidazole compounds and pharmaceutical | PAM, CHRM3, AZI2 | TRPV1 16/4885SCN5A 835/4885SCN9A 1549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.